SOUTH SAN FRANCISCO, Calif., Sept. 2, 2024 /PRNewswire/ — IgGenix, Inc., a preclinical antibody discovery and development company taking a revolutionary approach to address IgE-mediated diseases, presented exciting data on the company’s lead candidate, IGNX001, an IgG4 monoclonal…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.